Helen Torley , , M.B. Ch. B., M.R.C.P. , , President, Chief Executive Officer and member of the Board of Directors

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-U.S. markets and in particular, in Europe.

Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland.

She received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P). Dr. Torley is a member of the board of directors for Quest Diagnostics. She is also a member of the Health Section Governing Board of BIO, the Biotechnology Innovation Organization, and chair of BIO’s Workforce Development, Diversity and Inclusion committee.

Alison A. Armour , , M.B. Ch.B., B.Sc., M.Sc., M.D., FRCR, FRCP , , Senior Vice President, Head of Research and Development

Dr. Armour brings to Halozyme significant experience in all stages of oncology drug development, over 15 years of practice as a clinical oncologist, and a strong record of overseeing successful regulatory submissions. Dr. Armour joined Halozyme in May 2019 as Senior Vice President of Research and Development. She is responsible for Halozyme’s research, clinical development, regulatory, safety and pharmacovigilance efforts.

Prior to Halozyme, Dr. Armour served as the Chief Medical Officer at Endocyte, where she was responsible for the company’s clinical division, including all medical, clinical operations, regulatory, data management and pharmacovigilance activities. Prior to this role, she served as Vice President of Development and team lead for TYKERB® at GSK and then at Novartis. Earlier in her career, Dr. Armour also served as global medical science director at AstraZeneca.  She has co-authored two textbooks and more than 60 publications.

Dr. Armour received her B.Sc. in Biochemistry, her M.B., Ch.B. MSc, and Doctorate of Medicine from the University of Glasgow; her FRCR at the Royal College of Radiologists London, UK and her FRCP at the Royal College of Physicians in London, UK, for contributions to the field of oncology.

Dimitrios Chondros , , , Senior Vice President, Chief Medical Officer

Dr. Chondros brings to Halozyme broad experience directing complex clinical development and companion diagnostic programs toward global regulatory approvals and preparing for market entry. Dr. Chondros joined Halozyme in 2015 as Vice President of Clinical Development and assumed CMO responsibilities in 2017. Throughout his career, Dr. Chondros has managed cross functional teams across several key functions, including Clinical Science, Safety, Regulatory Affairs, Biostatistics, Research, Biomarkers, Clinical Pharmacology, Medical Affairs and Clinical Operations. He has also managed relationships with physicians and scientists across global sites.

Prior to Halozyme, he held positions of increasing responsibility at Genentech in the Product Development Oncology division and served as a member of the Antiangiogenesis and Oncology Signaling Franchise Leadership Teams. He played a leadership role for Avastin®, where he was accountable for all global development activities in gastrointestinal cancers, including the regulatory approvals for metastatic colorectal cancer. Prior to Genentech, he was Medical Director at Cell Genesys, where he directed the clinical development of an investigational immunotherapy for prostate cancer. Dr. Chondros has worked for the biopharmaceutical industry in Europe, China and USA.

Dr. Chondros studied medicine at the RWTH Aachen University in Germany and received his M.D. from the University of Zürich, Switzerland. He is a board certified general surgeon with experience as clinical trial investigator in numerous indications.

William J. Fallon , , , Senior Vice President, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances

Mr. Fallon brings to Halozyme a long record of biotechnology manufacturing and development expertise. Mr. Fallon joined Halozyme in 2006 as Vice President, Manufacturing & Operations. He is responsible for leading strategy and operations for the ENHANZE® business, including direct management of strategic alliances and all aspects of manufacturing, supply chain, quality assurance and quality control.

Prior to Halozyme, he served as President and Chief Executive Officer of Cytovance Biologics, a contract manufacturing organization that provides manufacturing and development services to the biotechnology industry. From 2001 to 2003, he was Vice President of Technical Operations at Genzyme Corporation, having held the same position at Novazyme Pharmaceuticals, Inc. prior to its acquisition by Genzyme in 2001. Mr. Fallon joined Novazyme from Transkaryotic Therapies, where he was Vice President of Manufacturing from 1998 to 2001. From 1993 to 1998, he was employed in several management positions for the Ares-Serono Group, including Vice President, U.S. Manufacturing Operations. In this role, he served as general manager, overseeing the production and distribution of all of Serono's approved biotechnology products in the U.S. From 1990 to 1992, he was Director of Manufacturing for Centocor, Inc. His prior experience also includes various management and operational roles at Invitron Corporation and Travenol-Genentech Diagnostics.

Mr. Fallon received his B.S. in Marine Science and his B.A. in Biology from Long Island University, and his M.S. in Biology from Northeastern University.

Ed Gemo , , , Vice President, Chief Information & Security Officer

Mr. Gemo brings to Halozyme more than three decades of experience developing information systems and infrastructure to support biotechnology commercialization. Mr. Gemo joined Halozyme in 2015 as Vice President and Chief Information & Security Officer. He is responsible for Information Technology and Site Operations, with a strong focus on implementing the systems, practices and procedures to help Halozyme scale while also ensuring the security of our information assets and the safety and security of our sites.

Prior to Halozyme, Mr. Gemo served as the Senior Vice President and Chief Information Officer at InterMune where he led the build of the Commercial technology platforms necessary for the successful launch of Esbriet®. Prior to that he was the Vice President and Chief Information Officer at Onyx Pharmaceuticals where he led the IT team in implementing many large scale platforms that helped Onyx scale rapidly, including key commercial platforms needed for the successful launch of Kyprolis®.

Before joining Onyx, Mr. Gemo had positions of increasing responsibilities for 29 years at Pfizer, including leading Pfizer’s Global Commercial Solution Center where he was responsible for all the tools and technology used by the Commercial organization, including Customer Relationship Management (CRM), Closed Loop Marketing (CLM), Multi-Channel Marketing and Campaign Management.

Mr. Gemo received his B.S. in Computer Science from Brooklyn College and his MBA in Information Systems from Pace University.

Benjamin J. Hickey , , , Senior Vice President, Chief Commercial Officer

Mr. Hickey brings to Halozyme a long track record of leading commercial teams, including launch teams, for innovative oncology treatments. Mr. Hickey joined Halozyme in September 2018 as Senior Vice President, Chief Commercial Officer. He is responsible for the global commercial strategy for the company’s current and future oncology portfolio.

Prior to Halozyme Mr. Hickey served as the General Manager, UK & Ireland at Bristol-Myers Squibb overseeing an organization of more than 300 people across the virology, immuno-science, oncology and cardiovascular disease businesses. Throughout his 17-year career with Bristol-Myers Squibb, he held roles of increasing responsibility, including serving as Vice President Marketing, Immuno-Oncology where he led the commercialization of Yervoy® and oversaw the launch preparedness of Opdivo® across more than eight indications and Executive Director and Vice President, Hematology, responsible for all commercial activity for Sprycel®, Erbitux® and an investigational multiple myeloma asset. In addition, he served as the U.S. brand lead for Farxiga® which is used to help treat type 2 diabetes and held positions in U.S. Finance and U.S. and worldwide access and reimbursement.

Mr. Hickey received his B.S. in Management and his MBA from St. Johns University in Queens, New York.

Al Kildani , , , Vice President of Investor Relations and Corporate Communications

Mr. Kildani brings to Halozyme a unique perspective based on his diverse experience from both the financial and life sciences industries. Mr. Kildani joined Halozyme in November 2018 as Vice President of Investor Relations and Corporate Communications. He is responsible for developing and executing Halozyme’s investor relations strategy and serves as the primary contact for analysts and the investment community. Additionally, he oversees all aspects of corporate communications, including public relations and external and internal communications.

Prior to Halozyme, Mr. Kildani served as Vice President, Investor Relations and Business Development for Vital Therapies, Inc., where he was responsible for the overall strategy and external messaging to institutional investors and performed due diligence on potential business development opportunities. He previously held senior investor relations and corporate communications roles at Hologic, Inc. and Gen-Probe, Inc. Prior to these roles, Mr. Kildani spent over 12 years in the securities industry with a focus on life sciences companies. He was an analyst with Stark Investments, C.E. Unterberg, Towbin, and Pacific Growth Equities LLC.

Mr. Kildani received his B.S. in Business Administration from Boston College, and is a member of the National Investor Relations Institute (NIRI).

Michael J. LaBarre , , Ph.D. , , Vice President, Product Development and Regulatory Affairs

Dr. LaBarre brings to Halozyme strong expertise in chemistry, manufacturing and controls (CMC) and more than 20 years of experience across all aspects of biopharmaceutical research and development. Dr. LaBarre joined Halozyme in 2008. He is responsible for product development and regulatory affairs and is the lead expert on Halozyme’s ENHANZE® drug delivery technology.

Prior to Halozyme, he served as Vice President of Product Development at Paramount BioSciences, LLC, where he led the CMC efforts for all of the product development programs within Paramount’s portfolio companies. Prior to joining Paramount, Dr. LaBarre served in various research and development positions from 1995 to 2006 at Biogen Idec (IDEC from 1995 to 2004), where he had responsibility for analytical and formulation development, protein purification, and physicochemical/biochemical characterization supporting numerous IND and BLA submissions, including those for the commercial products RITUXAN® and ZEVALIN®. His last position with Biogen Idec was Director of Analytical and Protein Biochemistry within the Discovery Research group. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the Analytical Methods Development group and he began his career at Hybritech in San Diego, where he held positions in Regulatory Affairs and Manufacturing Technical Support, focusing on conjugated/radiolabeled antibody technologies and analytical chemistry.

Dr. LaBarre received his B.S. in Chemistry from Southampton College of Long Island University and his Ph.D. in Bioinorganic Chemistry from the University of Arizona.

Harry J. Leonhardt , , Esq. , , Senior Vice President, General Counsel and Corporate Secretary

Mr. Leonhardt brings to Halozyme more than 35 years of executive management, corporate legal, intellectual property, compliance, business development and mergers and acquisitions experience, with an extensive background in the biotechnology sector. Mr. Leonhardt joined Halozyme in April 2015 as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary. He is responsible for all legal matters.

Prior to Halozyme, he served as Senior Vice President, Legal and Compliance, and Corporate Secretary at Amylin Pharmaceuticals, Inc., a biotech company (acquired by Bristol Myers Squibb in September 2012). Prior to Amylin, he served as Senior Vice President, General Counsel and Corporate Secretary at Senomyx, Inc.; Executive Vice President, General Counsel and Corporate Secretary at Genoptix, Inc.; and Senior Vice President, General Counsel and Corporate Secretary at Nanogen, Inc.

Prior to relocating to San Diego, Mr. Leonhardt held positions of increasing responsibility at Allergan, Inc., including Chief Litigation Counsel and General Counsel for European Operations. Early in his career, he was an intellectual property litigator at Lyon & Lyon where he represented a number of prominent clients in the biotech, pharmaceutical and consumer products areas.

Mr. Leonhardt his B.S. in Pharmacy from the University of the Sciences in Philadelphia and his J.D. from USC Law School.

Michael E. Paolucci , , , Vice President and Chief Human Resources Officer

Mr. Paolucci brings to Halozyme deep experience as a senior advisor for executive management and Board members of dynamic and fast-growing companies and a reputation for developing human capital strategies that are aligned with increasing sustainable shareholder value. Mr. Paolucci joined Halozyme in July 2015 as Vice President and Chief Human Resources Officer. He is responsible for all aspects of Halozyme’s human capital strategies, programs and policies.

Prior to Halozyme, Mr. Paolucci served as the Executive Vice President, Chief Human Resources Officer for CareFusion. In this role, he was responsible for initiatives to attract, develop and retain employees, companywide human resource strategy and programs that resulted in sustained improvements in business performance.

Before CareFusion, he served as Executive Vice President of Human Resources at NuVasive, and also spent five years at Life Technologies where he was responsible for global compensation, benefits and HCM systems. He was also head of Human Resources for the Services division of Hewlett Packard and served in several leadership roles with EDS, which was acquired by Hewlett Packard. Prior to HP/EDS, he was a partner with the HR consulting firm Towers Perrin.

He received his B.S. in Finance from The Ohio State University. Mr. Paolucci is a member of the board of directors for Orthofix Medical Inc.

Laurie D. Stelzer , , , Senior Vice President & Chief Financial Officer

Ms. Stelzer brings to Halozyme an extensive finance and business background. Leading teams in Finance, Treasury, Investor Relations, Business Development and Emerging Markets. Ms. Stelzer joined Halozyme in June 2015 as Senior Vice President, Chief Financial Officer. She is responsible for the Finance, Business Development, Information Technology, Project Management, Facilities and Site Operations organizations.

Prior to Halozyme, Ms. Stelzer served as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc. Prior to that she was the Division CFO for the Regenerative Medicine Division and the Head of Investor Relations at Shire. Prior to Shire, Ms. Stelzer held positions of increasing responsibility for 15 years at Amgen, Inc., including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. Early in her career, she held various finance and accounting positions in the real estate and banking industries.

Ms. Stelzer received her B.S. in Accounting from Arizona State University and her MBA from the Anderson School at the University of California, Los Angeles. She is a member of the board of directors for Surface Oncology.

Homa Yeganegi , , , Senior Vice President, Global PEGPH20 Program Lead

Ms. Yeganegi brings to Halozyme extensive experience in building and leading oncology-focused Global Medical Affairs teams and has a demonstrated track record of success driving strategic data generation, opinion leader development and engagement, scientific strategy and community, including global medical information and scientific education. Ms. Yeganegi joined Halozyme in March 2016 as the Vice President of Global Medical and Scientific Affairs. As the Global Program Lead for PEGPH20 (pegvorhyaluronidase alfa), she is responsible for the commercialization strategy and operational planning for Halozyme’s investigational new drug.

Prior to Halozyme, Ms. Yeganegi served as the Vice President of Global Medical Affairs at Clovis Oncology Pharmaceuticals where she successfully supported the pre-launch activities for Rociletinib in non-small lung cancer in the U.S. and EU. She has also built and led oncology-focused Global Medical Affairs teams at Exelixis Pharmaceuticals and Onyx Pharmaceuticals.

Ms. Yeganegi received her B.S. in Biology from the University of Tehran, Iran, her M.S. in Neuroanatomy from the University of Western Australia and is completing her Ph.D. in Health Sciences.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.